5 September 2018 - Governments should have public plans match the superior coverage offered in private drug plans and cover more new drugs now in existing public plans.

The last window of opportunity to inform federal lawmakers about the implications of a national pharmacare plan might soon be closing. At the end of September, the Liberal government’s Advisory Council on the Implementation of National Pharmacare will wrap up its public consultation. There’s a lot at stake in the council’s deliberations.

As a universal single-payer public drug plan, national pharmacare would replace Canada’s current mixed public-private drug insurance system. The council has an obligation to tell the public the truth about how this change will affect Canadians’ access to medicines. There are several questions that require serious answers from the government.

Read Financial Post article